Analysts’ Weekly Ratings Changes for Wave Life Sciences (WVE)

Several analysts have recently updated their ratings and price targets for Wave Life Sciences (NASDAQ: WVE):

• 11/21/2024 – Wave Life Sciences had its price target raised by analysts at Mizuho from $19.00 to $22.00. They now have an “outperform” rating on the stock.
• 11/13/2024 – Wave Life Sciences was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 11/13/2024 – Wave Life Sciences had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
• 11/12/2024 – Wave Life Sciences had its price target raised by analysts at Truist Financial Co. from $17.00 to $36.00. They now have a “buy” rating on the stock.
• 11/4/2024 – Wave Life Sciences had its price target raised by analysts at B. Riley from $19.00 to $22.00. They now have a “buy” rating on the stock.
• 10/31/2024 – Wave Life Sciences had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
• 10/21/2024 – Wave Life Sciences had its price target raised by analysts at Royal Bank of Canada from $7.00 to $15.00. They now have a “sector perform” rating on the stock.
• 10/17/2024 – Wave Life Sciences had its price target raised by analysts at JPMorgan Chase & Co. from $13.00 to $17.00. They now have an “overweight” rating on the stock.
• 10/17/2024 – Wave Life Sciences had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
• 10/16/2024 – Wave Life Sciences was upgraded by analysts at Raymond James from an “outperform” rating to a “strong-buy” rating. They now have a $22.00 price target on the stock, up previously from $13.00.
• 10/16/2024 – Wave Life Sciences had its price target raised by analysts at Wells Fargo & Company from $11.00 to $22.00. They now have an “overweight” rating on the stock.
• 10/16/2024 – Wave Life Sciences had its price target raised by analysts at Leerink Partners from $20.00 to $22.00. They now have an “outperform” rating on the stock.
• 10/4/2024 – Wave Life Sciences had its price target raised by analysts at Royal Bank of Canada from $5.00 to $7.00. They now have a “sector perform” rating on the stock.
• 10/3/2024 – Wave Life Sciences had its price target raised by analysts at B. Riley from $11.00 to $19.00. They now have a “buy” rating on the stock.
• 9/27/2024 – Wave Life Sciences is now covered by analysts at JPMorgan Chase & Co.. They set an “overweight” rating and a $13.00 price target on the stock.

Wave Life Sciences Stock Up 3.3 %

WVE stock traded up $0.47 during mid-day trading on Monday, reaching $14.74. The company had a trading volume of 769,271 shares, compared to its average volume of 1,112,330. The stock’s 50-day simple moving average is $11.57 and its two-hundred day simple moving average is $7.84. The stock has a market capitalization of $2.25 billion, a P/E ratio of -13.28 and a beta of -1.20. Wave Life Sciences Ltd. has a one year low of $3.50 and a one year high of $16.74.

Insider Activity at Wave Life Sciences

In related news, CFO Kyle Moran sold 17,146 shares of the company’s stock in a transaction dated Wednesday, September 25th. The shares were sold at an average price of $9.00, for a total value of $154,314.00. Following the completion of the sale, the chief financial officer now owns 19,777 shares of the company’s stock, valued at $177,993. This represents a 46.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Paul Bolno sold 90,474 shares of the business’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $15.00, for a total transaction of $1,357,110.00. Following the sale, the chief executive officer now owns 268,585 shares in the company, valued at $4,028,775. This trade represents a 25.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 403,690 shares of company stock worth $5,675,883 in the last ninety days. 29.10% of the stock is owned by insiders.

Institutional Trading of Wave Life Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Wave Life Sciences by 23.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,512 shares of the company’s stock worth $37,000 after buying an additional 856 shares in the last quarter. Profund Advisors LLC acquired a new position in shares of Wave Life Sciences in the 2nd quarter worth $53,000. Principal Financial Group Inc. acquired a new stake in shares of Wave Life Sciences during the second quarter worth $74,000. Mackenzie Financial Corp raised its position in shares of Wave Life Sciences by 13.6% during the second quarter. Mackenzie Financial Corp now owns 15,887 shares of the company’s stock worth $79,000 after purchasing an additional 1,905 shares during the period. Finally, Point72 DIFC Ltd acquired a new position in shares of Wave Life Sciences in the 3rd quarter valued at $98,000. Institutional investors own 89.73% of the company’s stock.

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.